AstraZeneca PLC
AZN84.580USD
+0.810+0.97%
Đóng cửa 11/07, 16:00（ET）Báo giá bị trễ 15 phút
262.32BVốn hóa
27.91P/E TTM
Thêm thông tin về AstraZeneca PLC Công ty
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Thông tin của AstraZeneca PLC
Mã chứng khoánAZN
Tên công tyAstraZeneca PLC
Ngày IPOSep 21, 2007
Giám đốc điều hànhMr. Marc Dunoyer
Số lượng nhân viên94300
Loại chứng khoánOrdinary Share
Kết thúc năm tài chínhSep 21
Địa chỉ1 Francis Crick Avenue
Thành phốCAMBRIDGE
Sàn giao dịch chứng khoánLondon Stock Exchange
Quốc giaUnited Kingdom
Mã bưu điệnCB2 0AA
Điện thoại442073045000
Trang webhttps://www.astrazeneca.com/
Mã chứng khoánAZN
Ngày IPOSep 21, 2007
Giám đốc điều hànhMr. Marc Dunoyer
Lãnh đạo công ty của AstraZeneca PLC
Tên
Tên/Chức vụ
Chức vụ
Tỷ lệ sở hữu cổ phần
Thay đổi
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Ms. Diana Layfield
Ms. Diana Layfield
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Rene Haas
Mr. Rene Haas
Non-Executive Director
Non-Executive Director
--
--
Mr. Michel Demare
Mr. Michel Demare
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Aradhana Sarin, M.D.
Ms. Aradhana Sarin, M.D.
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
Xem thêm
Tên
Tên/Chức vụ
Chức vụ
Tỷ lệ sở hữu cổ phần
Thay đổi
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Phân tích doanh thu
Tiền tệ: USDThời gian cập nhật: T2, 6 Th10
Tiền tệ: USDThời gian cập nhật: T2, 6 Th10
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Theo Doanh nghiệpUSD
Tên
Doanh thu
Tỷ trọng
Farxiga
2.15B
15.59%
Tagrisso
1.81B
13.12%
Imfinzi
1.46B
10.55%
Ultomiris
1.18B
8.53%
Calquenc
872.00M
6.32%
Khác
6.33B
45.89%
Theo Khu vựcUSD
Tên
Doanh thu
Tỷ trọng
United States
6.32B
45.84%
Europe
3.07B
22.23%
EX-China
2.04B
14.82%
China
1.71B
12.40%
Established ROW
1.31B
9.53%
Theo Doanh nghiệp
Theo Khu vực
Theo Doanh nghiệpUSD
Tên
Doanh thu
Tỷ trọng
Farxiga
2.15B
15.59%
Tagrisso
1.81B
13.12%
Imfinzi
1.46B
10.55%
Ultomiris
1.18B
8.53%
Calquenc
872.00M
6.32%
Khác
6.33B
45.89%
Thống kê Cổ phần
Thời gian cập nhật: T6, 31 Th10
Thời gian cập nhật: T6, 31 Th10
Cổ đông
Loại Cổ đông
Cổ đông
Cổ đông
Tỷ trọng
PRIMECAP Management Company
1.33%
Wellington Management Company, LLP
1.11%
Capital International Investors
1.01%
T. Rowe Price International Ltd
0.99%
T. Rowe Price Associates, Inc.
0.68%
Khác
94.88%
Cổ đông
Cổ đông
Tỷ trọng
PRIMECAP Management Company
1.33%
Wellington Management Company, LLP
1.11%
Capital International Investors
1.01%
T. Rowe Price International Ltd
0.99%
T. Rowe Price Associates, Inc.
0.68%
Khác
94.88%
Loại Cổ đông
Cổ đông
Tỷ trọng
Investment Advisor
8.93%
Investment Advisor/Hedge Fund
5.91%
Research Firm
0.80%
Hedge Fund
0.60%
Bank and Trust
0.16%
Pension Fund
0.08%
Family Office
0.02%
Family Office
0.02%
Family Office
0.02%
Khác
83.48%
Cổ phần của tổ chức
Thời gian cập nhật: T4, 1 Th10
Thời gian cập nhật: T4, 1 Th10
Chu kỳ Báo cáo
Số lượng tổ chức
Cổ phiếu nắm giữ
Tỷ trọng
Thay đổi
2025Q3
2046
512.19M
16.51%
-34.27M
2025Q2
2025
530.44M
17.10%
-21.90M
2025Q1
2050
532.32M
17.16%
-23.25M
2024Q4
1985
546.17M
17.61%
+11.21M
2024Q3
1920
519.95M
16.76%
-17.37M
2024Q2
1910
530.80M
17.12%
-10.51M
2024Q1
1865
523.00M
16.86%
-21.20M
2023Q4
1838
520.78M
16.79%
-27.28M
2023Q3
1815
530.17M
17.10%
-14.80M
2023Q2
1812
525.36M
16.94%
-28.74M
Xem thêm
Hoạt động của Cổ đông
Tên
Cổ phiếu nắm giữ
Tỷ trọng
Thay đổi
Thay đổi %
Ngày
PRIMECAP Management Company
41.20M
1.33%
+538.61K
+1.32%
Jun 30, 2025
Wellington Management Company, LLP
34.34M
1.11%
-1.29M
-3.63%
Jun 30, 2025
Capital International Investors
31.40M
1.01%
+119.42K
+0.38%
Jun 30, 2025
T. Rowe Price International Ltd
30.71M
0.99%
+3.43M
+12.56%
Jun 30, 2025
T. Rowe Price Associates, Inc.
21.24M
0.68%
-8.57M
-28.75%
Jun 30, 2025
Managed Account Advisors LLC
21.15M
0.68%
-1.37M
-6.07%
Jun 30, 2025
Fisher Investments
20.70M
0.67%
+530.52K
+2.63%
Jun 30, 2025
Fidelity Management & Research Company LLC
18.04M
0.58%
-944.35K
-4.97%
Jun 30, 2025
Sanders Capital, LLC
14.53M
0.47%
-542.12K
-3.60%
Jun 30, 2025
Putnam Investment Management, L.L.C.
12.48M
0.4%
+184.41K
+1.50%
Jun 30, 2025
Xem thêm
ETF liên quan
Thời gian cập nhật: T4, 1 Th10
Thời gian cập nhật: T4, 1 Th10
Tên
Tỷ trọng
Amplify Weight Loss Drug & Treatment ETF
5.58%
VanEck Pharmaceutical ETF
4.97%
Invesco Nasdaq Biotechnology ETF
4.81%
ProShares Ultra Nasdaq Biotechnology
4.81%
Parnassus Value Select ETF
4.66%
Invesco QQQ Low Volatility ETF
4.19%
Roundhill GLP-1 & Weight Loss ETF
3.36%
Abacus FCF International Leaders ETF
3.28%
Global X Aging Population ETF
3.2%
Franklin Genomic Advancements ETF
3.05%
Xem thêm
Amplify Weight Loss Drug & Treatment ETF
Tỷ trọng5.58%
VanEck Pharmaceutical ETF
Tỷ trọng4.97%
Invesco Nasdaq Biotechnology ETF
Tỷ trọng4.81%
ProShares Ultra Nasdaq Biotechnology
Tỷ trọng4.81%
Parnassus Value Select ETF
Tỷ trọng4.66%
Invesco QQQ Low Volatility ETF
Tỷ trọng4.19%
Roundhill GLP-1 & Weight Loss ETF
Tỷ trọng3.36%
Abacus FCF International Leaders ETF
Tỷ trọng3.28%
Global X Aging Population ETF
Tỷ trọng3.2%
Franklin Genomic Advancements ETF
Tỷ trọng3.05%
Cổ tức
Tổng cộng
20.90B
USD đã được phân phối dưới dạng cổ tức trong 5 năm qua.
Ngày
Cổ tức
Ngày ghi sổ
Ngày thanh toán
Ngày không hưởng cổ tức
Feb 06, 2025
AZN.NB Interim Cash Dividend of gross USD 1.05 paid on Mar 24, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Mar 24, 2025
Feb 21, 2025
Jul 25, 2024
AZN.NB Final Cash Dividend of gross USD 0.5 paid on Sep 09, 2024 going ex on Aug 09, 2024
Aug 09, 2024
Sep 09, 2024
Aug 09, 2024
Feb 08, 2024
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 25, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Mar 25, 2024
Feb 22, 2024
Jul 28, 2023
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 11, 2023 going ex on Aug 10, 2023
Aug 11, 2023
Sep 11, 2023
Aug 10, 2023
Feb 10, 2023
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 27, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Mar 27, 2023
Feb 23, 2023
Aug 01, 2022
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 12, 2022 going ex on Aug 11, 2022
Aug 12, 2022
Sep 12, 2022
Aug 11, 2022
Feb 10, 2022
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 28, 2022 going ex on Feb 24, 2022
Feb 25, 2022
Mar 28, 2022
Feb 24, 2022
Aug 02, 2021
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 13, 2021 going ex on Aug 12, 2021
Aug 13, 2021
Sep 13, 2021
Aug 12, 2021
Feb 11, 2021
AZN.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2021 going ex on Feb 25, 2021
Feb 26, 2021
Mar 29, 2021
Feb 25, 2021
Jul 30, 2020
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 14, 2020 going ex on Aug 13, 2020
Aug 14, 2020
Sep 14, 2020
Aug 13, 2020
Xem thêm
Chia tách cổ phiếu
Ngày
Loại
Tỷ lệ
Không có dữ liệu
Ngày
Loại
Tỷ lệ
Không có dữ liệu
